EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Safety of Estrogen-Based Feminizing Gender-Affirming Hormone Therapy: A Practical Endocrine Approach to Risk Stratification and Monitoring

Jagoda Kissock

Canadian Diabetes & Endocrinology Today · 25.05.2026 · 10-16

DOI: 10.58931/cdet.2026.4150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Diabetes & Endocrinology Today, online erschienen am 25.05.2026. Verfasst von Jagoda Kissock. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Estrogen-based feminizing hormone therapy is a cornerstone of care for transfeminine and gender-diverse individuals. Its benefits are well established, including improvements in gender dysphoria, mental health, and overall quality of life, with meaningful downstream effects on social functioning and long-term well-being. Much of the historical concern regarding safety largely reflects earlier use of ethinyl estradiol, which was associated with substantially increased risks of venous thromboembolism (VTE) and cardiovascular events. Contemporary practice has shifted toward the use of 17β-estradiol delivered orally, transdermally, or by injection, alongside more individualized dosing, and attention to baseline risk. This transition has materially improved the safety profile of therapy. The primary safety concern remains VTE, alongside evolving considerations related to cardiovascular risk and malignancy screening. Contemporary data suggest that these risks are both predictable and modifiable, allowing clinicians to individualize therapy without compromising gender-affirming outcomes. This review provides a clinically focused framework for risk stratification, route selection, and monitoring of estrogen-based feminizing therapy.

Zitieren

APA

Kissock, J. (2026). Safety of Estrogen-Based Feminizing Gender-Affirming Hormone Therapy: A Practical Endocrine Approach to Risk Stratification and Monitoring. Canadian Diabetes & Endocrinology Today, 10-16. https://doi.org/10.58931/cdet.2026.4150

Vancouver

Kissock J. Safety of Estrogen-Based Feminizing Gender-Affirming Hormone Therapy: A Practical Endocrine Approach to Risk Stratification and Monitoring. Canadian Diabetes & Endocrinology Today. 2026:10-16. doi:10.58931/cdet.2026.4150

BibTeX
@article{Kissock2026,
  author = {Kissock, Jagoda},
  title = {Safety of Estrogen-Based Feminizing Gender-Affirming Hormone Therapy: A Practical Endocrine Approach to Risk Stratification and Monitoring},
  journal = {Canadian Diabetes & Endocrinology Today},
  year = {2026},
  pages = {10--16},
  doi = {10.58931/cdet.2026.4150}
}
Kostenlos starten →